News

Neonatal abstinence syndrome risk varies with modifiable factors

View on the News

Time for routine screening

Neonatal abstinence syndrome is a rapidly growing problem, increasing 16-fold in Tennessee in 13 years. At a rate of 12 cases per 1,000 births in 2013, the incidence is now 10 times more likely than group B strep sepsis, congenital deafness, or dislocated hips, and many times more likely than a bilirubin of 20. So screening for it must become standard newborn care.

Although the American Academy of Pediatrics 2012 guidelines (Pediatrics 2012;129:e540-60) noted that 45-87 out of 1,000 mothers are using illicit drugs during pregnancy, this new study indicates that use of prescription opioids during pregnancy has been increasing and is associated with this rise in NAS. The use of any opioids during pregnancy (28%) now matches the rate of any alcohol (23.7%) and tobacco use (27.7%). Chronic users of opioids are fewer in number, but much more likely to yield withdrawal in the neonate.

The article identifies cofactors (cigarette and selective serotonin reuptake inhibitor use) that increase the likelihood of a given amount of maternal opiate use leading to clinical NAS. So the use of those substances should be solicited in history along with the types, frequency, and duration of any opioid use. It would be ideal if this information was collected during the obstetric admission process along with maternal blood type, group B strep status, hepatitis B, and other labs. Observation for signs of withdrawal deserves as much attention as that paid to getting the hearing screen done and the bilirubin checked. It is harming more newborns.

Kevin T. Powell, M.D., Ph.D., is a pediatric hospitalist and clinical ethics consultant living in St. Louis. He said that he had no relevant financial disclosures.


 

FROM PEDIATRICS

References

Infants born to women taking prescription opioids were more likely to have neonatal abstinence syndrome (NAS) if their mothers smoked tobacco or took selective serotonin reuptake inhibitors (SSRIs), according to a recent study. Cumulative opioid exposure and opioid type (maintenance and long-acting) also increased the risk of NAS.

“The American Academy of Pediatrics recommends that all opioid-exposed infants be observed in the hospital for 4 to 7 days after birth. However, our data suggest there was a wide variability in an infant’s risk of drug withdrawal based on opioid type, dose, SSRI use, and number of cigarettes smoked per day by the mother,” reported Dr. Stephen W. Patrick of Vanderbilt University, Nashville, Tenn. “Future studies should evaluate new care models for opioid-exposed infants at different risk levels of developing NAS,” wrote Dr. Patrick and his associates [Pediatrics 2015 April 13 [doi: 10.1542/peds.2014-3299]).

Dr. Patrick’s team analyzed prescription data and vital statistics of 112,029 pregnant women and their newborns who were enrolled in the Tennessee Medicaid program between 2009 and 2011. Of these, 28% of the women filled at least one prescription for opioids; these included 96.2% taking short-acting medications, 2.7% receiving maintenance treatment for substance use disorders and 0.6% taking long-acting medications.

Among women taking prescription opioids, 5.3% had depression, 4.3% had an anxiety disorder, 41.8% smoked, 4.3% had been prescribed SSRIs within 30 days before birth, 8.3% had headache or migraine, and 23.7% had musculoskeletal disease, compared to 2.7%, 1.6% and 25.8%, 1.9%, 2.0% and 5.8%, respectively, for mothers not taking opioids.

Nearly a third of women on maintenance therapy (29.3%) had infants with NAS while 14.7% of mothers taking long-acting opioids and 1.4% of women taking short-acting preparations had newborns with NAS. Newborns were twice as likely to develop NAS if their mothers took SSRIs (odds ratio, 2.08), and their risk of NAS increased in a dose-response fashion with the number of daily cigarettes their mothers smoked.

NAS rates nearly doubled during the course of the study, landing at 10.7 per 1,000 births in the final year. Among the 1,086 newborns diagnosed with NAS, 21.2% had low birth weight, 16.7% were preterm, 28.7% had respiratory diagnoses, 13.1% had feeding difficulties, 7.2% had sepsis, and 3.7% had seizures. Among those exposed to opioids who did not develop NAS, 11.8% had low birth weight, 11.6% were preterm, 10.1% had respiratory diagnoses, 2.6% had feeding difficulties, 2.3% had sepsis and 0.4% had seizures. Among unexposed newborns, 9.9% had low birth weight, 11% were preterm, 8.8% had respiratory diagnoses, 2.3% had feeding difficulties, 1.9% had sepsis, and 0.3% had seizures.

“Public health efforts should focus on limiting inappropriate [opioid pain relievers] and tobacco use in pregnancy,” the authors wrote. “Prescribing opioids in pregnancy should be done with caution because it can lead to significant complications for the neonate.”

The research was funded by the Tennessee Department of Health and the National Institutes of Health. The authors reported no disclosures.

Recommended Reading

Uterus transplantation: Medical breakthrough or surgical folly?
MDedge ObGyn
Examining the success of folic acid supplementation
MDedge ObGyn
10 evidence-based recommendations to prevent surgical site infection after cesarean delivery
MDedge ObGyn
Mother dies after cesarean delivery: $4.5M verdict
MDedge ObGyn
Glyburide in pregnancy linked to respiratory distress, NICU admission
MDedge ObGyn
cfDNA testing benefits extend to routine aneuploidy screening population
MDedge ObGyn
VBAC model as accurate for two prior cesareans as for one
MDedge ObGyn
Worse melanoma outcomes found in pregnant women
MDedge ObGyn
Cosmetic procedures in pregnancy
MDedge ObGyn
Prenatal drug exposure alters brain’s organization
MDedge ObGyn